Literature DB >> 17043708

The importance of pelvic lymph node dissection in men with clinically localized prostate cancer.

Mohamad E Allaf, Alan W Partin, H Ballentine Carter.   

Abstract

Despite advances in noninvasive staging, pelvic lymph node dissection (PLND) remains the most accurate means of detecting lymph node metastases in men with clinically localized prostate cancer. Nomograms exist that can identify patients at low risk for lymphatic metastases according to preoperative information. In general, it seems reasonable to omit PLND in men with a biopsy Gleason sum of 6 or less and a prostate-specific antigen level of 10 ng/mL or less. Ultimately, however, this decision should be made according to physician and patient preference, considering the low contemporary morbidity associated with PLND. When PLND is performed, studies suggest that an extended dissection maximizes the detection rate of nodal involvement. Retrospective data indicate that an extended dissection might play a therapeutic role in a subset of patients with a limited lymph node burden. However, this might be an artifact of stage migration, and prospective studies are needed to evaluate this further.

Entities:  

Year:  2006        PMID: 17043708      PMCID: PMC1578548     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  47 in total

1.  Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?

Authors:  Pia Bader; Fiona C Burkhard; Regula Markwalder; Urs E Studer
Journal:  J Urol       Date:  2003-03       Impact factor: 7.450

2.  Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma.

Authors:  S Conrad; M Graefen; U Pichlmeier; R P Henke; P G Hammerer; H Huland
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

Review 3.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.

Authors:  M Han; A W Partin; C R Pound; J I Epstein; P C Walsh
Journal:  Urol Clin North Am       Date:  2001-08       Impact factor: 2.241

4.  The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma.

Authors:  E D Crawford; J T Batuello; P Snow; E J Gamito; D G McLeod; A W Partin; N Stone; J Montie; R Stock; J Lynch; J Brandt
Journal:  Cancer       Date:  2000-05-01       Impact factor: 6.860

5.  Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques.

Authors:  N N Stone; R G Stock; P Unger
Journal:  J Urol       Date:  1997-11       Impact factor: 7.450

6.  The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.

Authors:  A R Feinstein; D M Sosin; C K Wells
Journal:  N Engl J Med       Date:  1985-06-20       Impact factor: 91.245

Review 7.  The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy.

Authors:  J S Wolf; M Cher; M Dall'era; J C Presti; H Hricak; P R Carroll
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

8.  Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.

Authors:  D L Bluestein; D G Bostwick; E J Bergstralh; J E Oesterling
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

9.  Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy.

Authors:  A R Sgrignoli; P C Walsh; G D Steinberg; M S Steiner; J I Epstein
Journal:  J Urol       Date:  1994-10       Impact factor: 7.450

10.  Preoperative assessment of prostatic carcinoma by computerized tomography. Weaknesses and new perspectives.

Authors:  C E Engeler; N F Wasserman; G Zhang
Journal:  Urology       Date:  1992-10       Impact factor: 2.649

View more
  5 in total

Review 1.  Unmet needs in the prediction and detection of metastases in prostate cancer.

Authors:  Oliver Sartor; Mario Eisenberger; Michael W Kattan; Bertrand Tombal; Frederic Lecouvet
Journal:  Oncologist       Date:  2013-05-06

Review 2.  Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: evolving contribution of PET in this setting.

Authors:  Thomas C Kwee; Sandip Basu; Drew A Torigian; Babak Saboury; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-12       Impact factor: 9.236

Review 3.  Comparison of perioperative complications for extended vs standard pelvic lymph node dissection in patients undergoing radical prostatectomy for prostate cancer: a meta-analysis.

Authors:  Jerry Kong; Benjamin Lichtbroun; Joshua Sterling; Yaqun Wang; Qingyang Wang; Eric A Singer; Thomas L Jang; Saum Ghodoussipour; Isaac Yi Kim
Journal:  Am J Clin Exp Urol       Date:  2022-04-15

4.  Reduction in incidence of lymphocele following extraperitoneal radical prostatectomy and pelvic lymph node dissection by bilateral peritoneal fenestration.

Authors:  Jens-Uwe Stolzenburg; Johanna Wasserscheid; Robert Rabenalt; Minh Do; Thilo Schwalenberg; Alan McNeill; Costantinos Constantinides; Panagiotis Kallidonis; Roman Ganzer; Evangelos Liatsikos
Journal:  World J Urol       Date:  2008-09-07       Impact factor: 4.226

5.  MRI-Derived Restriction Spectrum Imaging Cellularity Index is Associated with High Grade Prostate Cancer on Radical Prostatectomy Specimens.

Authors:  Michael A Liss; Nathan S White; J Kellogg Parsons; Natalie M Schenker-Ahmed; Rebecca Rakow-Penner; Joshua M Kuperman; Hauke Bartsch; Hyung W Choi; Robert F Mattrey; William G Bradley; Ahmed Shabaik; Jiaoti Huang; Daniel J A Margolis; Steven S Raman; Leonard S Marks; Christopher J Kane; Robert E Reiter; Anders M Dale; David S Karow
Journal:  Front Oncol       Date:  2015-02-17       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.